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Bisphosphonate’s and Intermittent Parathyroid 
Hormone’s Effect on Human Spinal Fusion:  
A Systematic Review of the Literature
Michael A. Stone1, Andre M. Jakoi1, Justin A. Iorio2, Martin H. Pham3, Neil N. Patel1, 
Patrick C. Hsieh3, John C. Liu3, Frank L. Acosta3, Raymond Hah1, Jeffrey C. Wang1  
1Department of Orthopaedic Surgery, Keck School of Medicine of USC, Los Angeles, CA, USA
2Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, USA
3Department of Neurological Surgery, Keck School of Medicine of USC, Los Angeles, CA, USA  
There has been a conscious effort to address osteoporosis in the aging population. As bisphosphonate and intermittent parathyroid 
hormone (PTH) therapy become more widely prescribed to treat osteoporosis, it is important to understand their effects on other 
physiologic processes, particularly the impact on spinal fusion. Despite early animal model studies and more recent clinical studies, 
the impact of these medications on spinal fusion is not fully understood. Previous animal studies suggest that bisphosphonate therapy 
resulted in inhibition of fusion mass with impeded maturity and an unknown effect on biomechanical strength. Prior animal studies 
demonstrate an improved fusion rate and fusion mass microstructure with the use of intermittent PTH. The purpose of this study was 
to determine if bisphosphonates and intermittent PTH treatment have impact on human spinal fusion. A systematic review of the 
literature published between 1980 and 2015 was conducted using major electronic databases. Studies reporting outcomes of human 
subjects undergoing 1, 2, or 3-level spinal fusion while receiving bisphosphonates and/or intermittent PTH treatment were included. 
The results of relevant human studies were analyzed for consensus on the effects of these medications in regards to spinal fusion. 
There were nine human studies evaluating the impact of these medications on spinal fusion. Improved fusion rates were noted in 
patients receiving bisphosphonates compared to control groups, and greater fusion rates in patients receiving PTH compared to 
control groups. Prior studies involving animal models found an improved fusion rate and fusion mass microstructure with the use 
of intermittent PTH. No significant complications were demonstrated in any study included in the analysis. Bisphosphonate use in 
humans may not be a deterrent to spinal fusion. Intermittent parathyroid use has shown early promise to increase fusion mass in both 
animal and human studies but further studies are needed to support routine use.
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Introduction
As the average age of the population increases, and 
subsequently the diagnosis of osteoporosis within the 
aging population, there has been a conscious effort to 
address this health condition. Osteoporosis is one of the 
most common metabolic bone diseases in the United 
States [1]. As bisphosphonate and intermittent parathyroid 
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hormone (PTH) therapy become more widely prescribed 
to treat osteoporosis, it is important to understand their 
effect on other physiologic processes. Bisphosphonates 
inhibit osteoclastic bone resorption and have a direct ana-
bolic effect on bone formation. Non-nitrogen containing 
bisphosphonates are metabolized into a nonfunctional ad-
enosine triphosphate (ATP) analog which induces osteo-
clast apoptosis. Nitrogen-containing bisphosphonates can 
be up to 1,000 times more potent in their action due to 
their nitrogen side-groups. This class of bisphosphonates 
inhibits protein prenylation in the mevalonate pathway 
and blocks farnesyl pyrophosphate synthase resulting in 
inhibition of the ruffled border formation. PTH exerts its 
effects via activation of cell surface receptors on bone and 
renal G-proteins [2]. With continuous administration, 
PTH favors bone reabsorption; however, with pulsed ad-
ministration, it favors bone formation [3]. PTH has been 
shown to increase cortical thickness without increasing 
porosity in osteoporotic patients. The commercially avail-
able form of PTH (Teriparatide) has been shown to de-
crease vertebral fracture risk in postmenopausal women 
with osteoporosis [3]. 
Of particular interest is the impact of bisphosphonates 
and PTH treatment on spinal fusion. Early studies on ani-
mal models have attempted to measure time to fusion and 
bone fusion mass outcomes. Recent studies have begun to 
investigate the clinical effect of these medications on spi-
nal fusion, but their impact remains poorly understood. 
A related study in distraction osteogenesis employed bo-
lus dosing of nitrogen-containing bisphosphonates and 
showed significant increases in callus volume, mineral 
content, and strength in treated animals, even in the pres-
ence of stress shielding [4]. Additionally, complications af-
ter lumbar interbody surgery, such as subsequent vertebral 
compression fractures, cage subsidence, and loosening of 
pedicle screws are most frequent in osteoporosis patients 
[5]. Osteoporosis treatment with these medications may 
be of benefit to mitigate these complications. 
The purpose of our study was to provide a comprehen-
sive review of the current literature regarding bisphospho-
nate use and PTH therapy in osteoporotic patients under-
going spinal fusion. 
Materials and Methods
1. Search strategy
A comprehensive search of the literature was performed 
for articles published between 1980 and October 2015 
evaluating the effects of bisphosphonates or PTH on spi-
nal fusion. The PubMed (MEDLINE) and BIOSIS data-
bases were queried using the multiple search terms (spinal 
fusion, pseudarthrosis, bisphosphonates, clodronate, iban-
dronate, etidronate, alendronate, risedronate, zoledronate, 
pamidronate, Forteo, teriparatide or PTH) (Table 1). Two 
independent reviewers screened the titles and abstracts of 
all the articles for appropriate inclusion. 
2. Study selection process
Records were retrieved from the electronic search results 
and exported to EndNote X7 (Thomson Reuters, New York, 
NY, USA) and all duplicates were removed. Two authors 
(A.J.K. and M.A.S.) independently reviewed and selected 
the relevant studies. The eligibility criteria was applied to 
the selected studies in which case the full text was available 
for review. Any disagreements were resolved by consensus. 
In the case where a consensus could not be reached the dis-
crepancy was resolved by a third author (NP). 
Exclusion criteria were: (1) studies that did not evalu-
ate spinal fusion (quality, biomechanics, histology), (2) 
studies lacking control subjects, (3) studies that did not 
perform statistical analysis or (4) case reports. The search 
strategy revealed 59 studies from the literature, further 
screening of the titles and abstracts of these articles iden-
tified 30 papers for review. Twenty-one studies were ex-
cluded as they pertained to non-human studies, and 3 of 
which were review papers. This left 9 articles for inclusion 
of our final review (Fig. 1) [6].
Relevant data were identified and extracted from the 
Table 1. Search terms
((“humans”[MeSH Terms] OR “humans”[All Fields] OR “human”[All Fields]) AND (“lumbosacral region”[MeSH Terms] OR (“lumbosacral”[All 
Fields] AND “region”[All Fields]) OR “lumbosacral region”[All Fields] OR “lumbar”[All Fields]) AND (“Nucl Eng Des/Fusion”[Journal] OR 
“fusion”[All Fields] OR “FUSION”[Journal] OR “fusion”[All Fields])) AND ((“diphosphonates”[MeSH Terms] OR “diphosphonates”[All Fields] OR 
“bisphosphonates”[All Fields]) OR (“parathyroid hormone”[MeSH Terms] OR (“parathyroid”[All Fields] AND “hormone”[All Fields]) OR 
“parathyroid hormone”[All Fields]))
Michael A. Stone et al.486 Asian Spine J 2017;11(3):484-493
full text of each study including demographic data, assess-
ment of fusion quality or mass, methodology of fusion 
assessment and statistical significance, if available. Some 
of the studies stratified data by treatment groups, and in 
these cases, the extracted data were appropriately strati-
fied to reflect this. The heterogeneity of the methodology 
used in the included studies precluded meta-analysis.
3. Level of evidence
Level of evidence of each study was independently graded 
by two of the authors using the criteria outlined by Wright 
et al. [7]. Any disagreements in the grading of level of 
evidence was resolved by a third reviewer. 
Results
Initially, 59 human and animal studies pertaining to 
adjuvant bisphosphonate and/or PTH for improvement 
of spinal fusion were retrieved from PubMed and Biosis. 
After review, 50 studies were excluded as they did not 
portend to human studies in addition to the criteria listed 
in Fig. 1 [6]. Nine studies that matched both the inclusion 
and exclusion criteria were included in our final analysis. 
Four studies were graded as Level III, four studies were 
graded as Level II, and one study was graded as Level 
I. All studies evaluated patients with osteoporosis con-
firmed with dual-energy X-ray absorptiometry (DEXA) 
with spinal stenosis, degenerative spondylolisthesis, and/
or foraminal stenosis. All patients underwent one, two or 
three level posterior lumbar fusion with instrumentation. 
All studies mentioned that they used local autograft for 
their graft materials, with Park et al. supplementing it with 
the use of iliac crest autograft and/or allograft bone and 
Nagahama et al. supplementing local autograft with Beta-
tricalcium phosphate. There was no mention of the use 
Id
en
tifi
ca
tio
n
Sc
re
en
in
g
El
ig
ib
ili
ty
In
cl
ud
ed
Literature search
   Databases: PubMed, MEDLINE, BIOSIS
   Limits: English-language articles only
Search results after duplicates removed 
(n=59)
Articles screened based on title 
and abstract Excluded (n=29)
Full-text articles assessed for 
eligibility (n=30)
Full-text articles excluded (n=21)
Non-human studies: 21
Reviews: 3
Studies included for final review 
(n=9)
PRISMA 2009 flow diagram
Fig. 1. PRISMA flow diagram for study inclusion (Data from Moher et al., PLoS Med 2009:6:e1000097 [6], on the basis of 
Open Access).
Studies evaluating 
bisphosphonates 
(n=9)
Studies evaluating 
teriparatide
(n=4)
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of bone morphogenic protein or other osteoconductive 
materials. 
Zoledronic acid was used in three studies, Risedronate 
in three studies, and Alendronate in three studies. Teripa-
ratide was used in four studies. Zoledronic acid was given 
as a 5 mg dose three days prior to surgery in one study [8], 
two weeks after surgery as single dose in another study 
[9], and three days postoperatively and yearly thereafter 
in the final study [10]. Risedronate dose was 2.5 mg oral 
daily two months before and continued ten months af-
ter surgery in one study [11], 17.5 mg and given weekly 
starting two months before surgery and continued for 
eight months after surgery in another study [12], and 
started three months before surgery in the final study [13], 
however they did not track which patients received Rise-
dronate versus Teriparatide postoperatively. Alendronate 
was administered as 35 mg weekly prior to surgery and 
continued until follow-up at one year in one study [14] 
and 91 mg weekly for at least one year in another study 
[15]. Teriparatide was given as a daily 20 μg subcutaneous 
dose in all studies. Dosing was given starting two months 
before surgery and continued for ten months after sur-
gery [11], in 3-month cycles [15], beginning two months 
before surgery and continued for eight months after sur-
gery [12], and the final study was given in short duration 
(less than six months) or long duration (greater than six 
months) groups [13]. Demographic information is listed 
in Table 2 [8-16]. 
1. Effect of bisphosphonates on spinal fusion
Nagahama et al. measured intervertebral fusion radio-
graphically with computed tomography (CT) scan at 
three, six, nine, and twelve months after single level poste-
rior lumbar interbody fusion. Patients were randomly as-
signed to begin alendronate (n=19, 35 mg/wk) or vitamin 
D (n=17, 1 µg/day) within one week after surgery and 
surgeons were blinded to the treatment protocol. Fusion 
was defined as less than 5 degrees of angular motion on 
flexion and extension radiographs at the fusion level and 
bridging cortical bone. Cage subsidence was measured 
and defined as greater than 2 mm of vertical migration 
from baseline. At one year postoperatively, fusion was ob-
served in 95% (18/19) of the alendronate group and 65% 
(11/17) of the control group (p=0.025). There were also 
higher rates of cage subsidence in the control group (5 pa-
tients) versus the alendronate group (1 patient), however 
this was not statistically significant (Table 3) [8-16].
Bone alkaline phosphatase was elevated by 52% at 1 
month postoperatively, but decreased to below baseline by 
Table 2. Demographic information
Study Design Level of evidence No.  Drug Dose Duration
Li et al. [8] Prospective I 82 Zoledronic acid 5 mg 1 Time infusion 3 days after 
surgery
Nagahama et al. 
[14]
Prospective II 36 Alendronate or 
alfacalcidol 
35 mg/wk Started 1 week after surgery 
and continued for 12 months
Park et al. [9] Retrospective III 44 Zoledronic acid 5 mg Single dose
Tu et al. [10] Retrospective III 64 Zoledronic acid 5mg 3 Days postoperative, then 
yearly
Kim et al. [16] Retrospective III 44 Alendronate 35 mg/wk Not recorded
Ohtori et al. [11] Prospective II 62 Teriparatide 
risedronate
Daily subcutaneous 
injection 20 μg daily 
2.5 mg
Administered for 2 months 
before and 10 months after 
surgery
Ohtori et al. [12] Prospective II 57 Teriparatide 
risedronate
Daily subcutaneous 
injection 20 μg 
17.5 mg weekly
Both started 2 months 
before surgery and continued 
8 months after surgery
Ohtori et al. [13] Retrospective III 45 Teriparatide 
risedronate
Daily 20 μg 17.5 mg 
weekly
<6 months, >6 months
Cho et al. [15] Prospective II 47 Teriparatide 
alendronate  
Daily subcutaneous 
injection 20 μg 91.37 
mg weekly
Started and continued for 
12 months after surgery
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6 months suggesting that alendronate decreased bone for-
mation after the early phase. Type 1 collagen cross-linked 
N-telopeptide, a marker of bone resorption, decreased 
to below baseline in the alendronate group suggesting 
inhibition of resorption immediately after surgery. The 
study was graded as Level II as it was underpowered due 
to small sample size, absence of inter-rater reliability data, 
use of non-validated fusion measures, and lack of true 
control arm (placebo or non-medicated) [14]. 
Li et al. [8] used CT with multi-planar reconstruction at 
six months postoperatively to evaluate intervertebral fu-
sion after transforaminal lumbar interbody fusion (TLIF) 
in a randomized, double-blind, placebo-controlled trial of 
82 subjects. The zoledronic acid group showed no statisti-
cal difference in nonunion rates compared to the control 
group at six months (27.9% versus 33.9%, p=0.60), and 
no differences at twelve months (11.5% versus 14.5%, 
p=0.82). There were no statistically significant differences 
in Oswestry disability index (ODI) scores. Biochemical 
measurements were also done which included serum 
calcium, phosphate, amino terminal propeptides of type I 
collagen (PINP), C-telopeptide of type I collagen (CTX), 
PTH and 25-hydroxyvitamin D. The zoledronic acid 
group significantly decreased PINP (p<0.0001) and CTX 
(p<0.0001) compared to controls in the postoperative pe-
riod, which reflects decreased bone formation and bone 
resorption respectively. The results of this study may differ 
from those of Nagahama et al. [14] because risedronate 
and alendronate have different pharmacokinetics, and 
different interbody techniques (TLIF and posterior lumbar 
interbody fusion [PLIF]) were used. This study was graded 
as Level I.
Park et al. [9] retrospectively reviewed 4 groups of pa-
tients who underwent 1 or 2-level posterolateral lumbar 
fusions for degenerative stenosis: group 1, autograft and 
zoledronic acid; group 2, allograft and zoledronic acid; 
Table 3. Assessment of fusion
Study Medication Treatment Fusion rate Fusion mass
Li et al. [8] Zoledronic acid 1, 2, or 3 Level TLIF                     - Not recorded
Nagahama et al. 
[14]
Alendronate or 
alfacalcidol 
1 Level PLIF 18/19 (95%) In the alendronate group 
11/17 (65%) Control group
Not recorded
Park et al. [9] Zoledronic 
acid
1 or 2 Level PLIF Group 1: bilateral posterolateral lumbar 
fusion with autogenous iliac and local bone 
grafting & zoledronic acid - 100% (11/11) 
Group 2: allograft and autograft bone & 
zoledronic acid - 100% (11/11) 
Group 3: autogenous iliac and local bone 
grafting - 100% (11/11) 
Group 4: allograft and autograft bone - 
82% (9/11)
Measured at 6 months 
Group 1: 8,814 mm3
Group 2: 8,035 mm3
Group 3: 8,383 mm3
Group 4: 7,550 mm3
Tu et al. [10] Zoledronic 
acid 
1 or 2 Level LIF 75% In the zoledronic acid group 
56% In the control group
Not recorded
Kim et al. [16] Alendronate 1 Level PLIF 66.7% In the alendronate group 
73.9% In the control group
Not recorded
Ohtori et al. [11] 
 
Teriparatide 
risedronate
1 or 2 Level PLF, 
Bilateral facet fusions
Not assessed Not recorded
Ohtori et al. [12] Teriparatide 
risedronate
1 or 2 Level PLF, 
Bilateral facet fusions
82% In teriparatide group, 
68% In risedronate group
Not recorded
Ohtori et al. [13] Teriparatide 
risedronate
1 or 2 Level PLF, 
Bilateral facet fusions
70% Fusion in the risedronate group 
78% Fusion in the short-duration teriparatide 
treatment group 
86% Fusion in the long-duration treatment 
group
Not recorded
Cho et al. [15] Teriparatide 
alendronate
1 or 2 Level PLIF 93% In teriparatide group, 
96% In alendronate group
Not recorded
TLIF, transforaminal lumbar interbody fusion; PLIF, posterior lumbar interbody fusion; LIF, lumbar interbody fusion; PLF, posterolateral lumbar fusion.
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group 3, autograft only; and group 4, allograft only. A 
blinded assessor interpreted radiographs and three-di-
mensional CT which were performed up to 6 months af-
ter surgery to quantify fusion masses [9]. Groups 1, 2, and 
3 achieved a 100% fusion rate and Group 4 exhibited a 
fusion rate of 82%; however, there were no significant dif-
ferences between groups (p>0.05). Similarly, fusion mass 
volumes were not different between groups (p>0.05). All 
groups showed significant improvement in visual anana-
log scale (VAS), ODI and SF-36 scores, however there 
were no significant differences between groups in any of 
these clinical outcomes [9]. This study was graded as level 
III because it was underpowered, retrospective design, 
small sample sizes, and short-term follow-up.  
Tu et al. [10] performed a retrospective review compar-
ing zoledronic acid and a control group undergoing one 
or two-level lumbar interbody fusion. Fusion was assessed 
with radiographic evaluation and analysis of pedicle screw 
loosening, vertebral compression fractures, subsidence, 
and lucencies between vertebral bodies which indicated 
nonunion. Patients were followed for two years. The fi-
nal fusion rate was higher in the zoledronic acid group 
compared to control group (75% versus 56%), however 
there is no mention if these numbers were able to reach 
statistical significance. Vertebral compression fractures, 
pedicle screw loosening, and cage subsidence were all sig-
nificantly lower in the zoledronic acid group compared to 
control group (19% versus 51%), (18% versus 45%), (28% 
versus 54%), respectively. There were no differences in 
VAS and ODI scores up to 9 months postoperatively, how-
ever both scores were significantly lower in the zoledronic 
acid group at 2 years [10]. This study was graded level III 
and is limited by its retrospective design, inability to de-
termine if similar interbody techniques were used among 
all patients, failure to perform CT imaging on all patients, 
use of only one imaging reviewer, and lack of statistical 
analysis regarding fusion rates between groups. 
Kim et al. [16] performed a retrospective analysis of 44 
patients with osteoporosis undergoing single level PLIF 
comparing alendronate to control group. Radiographs 
were evaluated for evidence of spinal fusion and flexion 
extension views. Modic endplate changes were recorded. 
They showed a 66.7% fusion rate in the alendronate group 
and 73.9% fusion rate in the control group which was not 
significantly different. The authors did not record dura-
tion of bisphosphonate treatment [16]. 
2. Effect of PTH on spinal fusion
Ohtori et al. [12] reported their results of a prospective 
study of postmenopausal women with osteoporosis who 
underwent one- or two-level instrumented lumbar pos-
terolateral fusion with local bone graft for degenerative 
spondylolisthesis. Fifty-seven women were divided into 
a teriparatide groups (n=29, 20 µg subcutaneous [SC] 
daily) or a bisphosphonate group (n=28, 17.5 mg of oral 
risedronate weekly). At 1-year after surgery, the authors 
found that the rate of bone union as evaluated by CT was 
82% in the teriparatide group and 68% in the risedronate 
group (p=0.02). The rate of bone fusion was also faster in 
patients who received teriparatide (mean, 8±2.5 months) 
rather than risedronate (mean, 9.7±2 months) (p=0.03). 
Instability as determined by radiography (greater than 
1.5° of movement between flexion and extension) was 
more common in the risedronate group (26% versus 16% 
of instrumented segments, p=0.02), but measurements 
may have been obscured by instrumentation and implants 
rather than union, as the implants may have provided 
immediate stability. There were no differences in VAS or 
ODI scores at follow-up between the two groups. This 
study was graded as Level III because of small sample 
size and presence of comparison group, but lack of a non-
medicated control group.
In 2013, Ohtori et al. [11] prospectively studied pedicle 
screw loosening after lumbar fusion surgery in 62 post-
menopausal women with osteoporosis who were treated 
with teriparatide (n=20, 20 µg SC daily), a bisphospho-
nate (n=20, 2.5 mg of oral risedronate daily), or without 
medications (n=22). All patients underwent 1- or 2-level 
instrumented posterolateral fusions with local bone graft 
for spondylolisthesis and continued the treatment medi-
cation for 10 months. Pedicle screw loosening was deter-
mined by lucent zones around screws on radiographs and 
CT imaging for up to 1-year after surgery. Readings were 
performed by three observers and screws were considered 
loose if two observers identified lucent zones. At 1-year 
follow-up, the teriparatide group had significantly less 
pedicle screw loosening (7% on radiographs and 13% on 
CT) compared to the bisphosphonate (13% and 26%, re-
spectively) and non-medicated groups (15% and 25%, re-
spectively). There were no differences in screw loosening 
between the bisphosphonate and control group (p>0.05), 
and VAS and ODI scores were not different between the 
3 groups regardless of screw loosening. Diabetes, use of 
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anti-inflammatory medication, smoking status, and bone 
mineral density could not account for rates of screw loos-
ening between groups (p>0.05). This study was graded as 
Level III because surgeons were not blinded to the treat-
ment arm, sample sizes were limited, radiographic mea-
sure of screw loosening (lucency≥1 mm at bone-screw 
interface) has not been validated, and it is unclear if inter-
rater reliability was established.
A subsequent retrospective investigation by Ohtori et al. 
[13] investigated the most effective duration of teripara-
tide for osteoporotic women undergoing lumbar postero-
lateral fusion. All patients had a diagnosis of lumbar ste-
nosis with degenerative spondylolisthesis and underwent 
1- or 2-level instrumented fusion with local bone graft 
and bilateral facet fusions. Forty-five women were divided 
into 3 groups: short-term teriparatide (mean duration, 5.5 
months; 20 µg SC daily), long-term teriparatide (mean 
duration, 13 months; 20 µg SC daily), and a bisphospho-
nate group (mean duration, 13 months; 17.5 mg of oral 
risedronate weekly). All patients received teriparatide or 
risedronate for 3 months prior to surgery. At 1-year, union 
across the transverse processes on CT imaging for the 
risedronate, short-term, and long-term teriparatide groups 
was 70%, 78%, and 86%, respectively. Fusion in the teripa-
ratide groups was greater than the bisphosphonate group 
(p<0.05), and prevalence of union was greater in the long-
term versus short-term group (p=0.045). This study was 
graded Level III because of its small sample size, presence 
of comparison but lack of control group, and absence of 
standardized outcomes measures. Selection bias in whom 
to enroll is another limitation of this retrospective study. 
The authors also state that patients received bisphospho-
nates after treatment with teriparatide “for ethical reasons”.
Cho et al. [15] prospectively compared teriparatide 
and bisphosphonate therapy in 47 osteoporotic women 
who underwent PLIF with pedicle screw fixation for 
lumbar stenosis with instability. The teriparatide group 
(n=23) received a 20 µg daily subcutaneous dose for 
3-month cycles alternating with 3-week intervals of oral 
alendronate 91 mg weekly and the bisphosphonate group 
(n=24) received oral alendronate 91 mg weekly. Treat-
ment medications were prescribed for 1 year after surgery. 
At 24 months after surgery, there were no differences in 
interbody fusion rate, pedicle screw loosening, cage sub-
sidence, bone mineral density scores, or clinical outcome 
scores between groups. The study was graded as Level II 
because of nonrandom allocation to treatment groups and 
small sample size. Additional limitations are the cyclic 
teriparatide regimen, use of one imaging reviewer, lack of 
intra-rater reliability reporting, and utilization of a non-
validated fusion classification.
Discussion 
Anti-osteoporotic medications are being used more fre-
quently as adjunctive treatments for fusion in osteoporotic 
patients undergoing instrumented lumbar surgery. It has 
been estimated that at least 72% of Caucasian women over 
the age of 65 years and 93% over 75 years of age are candi-
dates for anti-osteoporotic medications [17]. In contrast, 
approximately 34% and 50% of Caucasian men over the 
ages of 65 and 75 years, respectively, are likely to be rec-
ommended for drug treatment [17]. The purpose of our 
study was to perform a systematic review of the effects of 
bisphosphonates and intermittent PTH on spinal fusion. 
At the time of our review, 9 studies of human subjects 
were available (4 retrospective and 5 prospective), two of 
which were randomized controlled trials. 
Bisphosphonates have been utilized in spinal fusion 
procedures because of their efficacy in fracture reduc-
tion in osteoporotic patients. Among all anti-resorptive 
medications, bisphosphonates are the only medications 
that are proven to reduce the rate of hip fractures in large, 
randomized controlled trials [18-20]. However, the ef-
fect of bisphosphonates on spinal fusion are less well-
established and results have been controversial [21,22]. 
Animal studies have shown increased size and density of 
fusion masses but decreased fusion rates [21], increased 
bone mineral content with improved fusion rates [22], 
improved bone-screw interface fixation after pedicle 
screw placement [23], and dose-dependent effects on 
graft incorporation [24-26]. Many of the previous stud-
ies involving animal studies which evaluated the effects 
of alendronate administered for several weeks before and 
after spinal fusion showed a negative effect on fusion rate 
[15,17]. Similarly, pamidronic acid administered for 4 
weeks preoperatively and then daily for 4 weeks postop-
eratively was also shown to have negative effects on spinal 
fusion in a rabbit model [27].
Bisphosphonate studies involving human subjects have 
not conclusively supported an improvement in fusion after 
lumbar surgery. All 8 studies included a bisphosphonate 
treatment group; however, 3 lacked a non-medicated con-
trol group, 3 studies were comparisons against teriparatide, 
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1 evaluated screw loosening but failed to mention fusion 
rates, and 1 included a vitamin D control group. Only one 
study found that a bisphosphonate was superior to vita-
min D via statistical analysis [14]; another study reported 
an approximately 20% greater fusion rate with zoledronic 
acid compared to controls but failed to report statisti-
cal significance [10]. Pain and functional outcomes after 
bisphosphonate treatment were not improved greater than 
that of controls in any study, but a reduction in secondary 
outcomes such as compression fractures and hip fractures 
has been found in several studies. Additionally, studies 
have shown that bisphosphonates may be used to increase 
bone-screw fixation in osteoporotic long bones [21] as 
well as improve bone-screw interface fixation in an exper-
imental spine models [23]. Biochemical markers support 
an alteration in bone formation and resorption which re-
sults in a larger and denser fusion mass; unfortunately, the 
ability to form a solid fusion is not improved.
Intermittent recombinant PTH appears to have a simi-
lar outcome record when comparing animal model stud-
ies to that of humans. Preclinical data has supported the 
use of intermittent PTH for lumbar spinal fusion. In three 
animal posterolateral fusion studies, the use of PTH had 
a positive effect on achieving faster fusion rates than that 
of the use of autograft only. In human studies, teriparatide 
treatment groups had earlier time to union compared to 
placebo for osteoporotic [24,28] patients with distal radii 
and pelvic fractures [29]. Promising results of teriparatide 
on bony healing have similarly been reported in spine pa-
tients. Rubery and Bukata [30] confirmed healing with CT 
scans and resolution of neck pain after delayed union of 
three type III odontoid fractures in osteoporotic females. 
However, the study is limited by a small sample size, ret-
rospective design, and variable durations of teriparatide 
treatment. Larger studies have also shown promising re-
sults for achieving solid fusion and reducing pedicle screw 
loosening, suggesting an improvement of bone quality in 
the marrow and pedicles [11-13]. Despite strong histolog-
ical evidence of improved fusion after PTH no differences 
in clinical outcomes have been established between PTH, 
bisphosphonates, and controls [11,12]. 
One study failed to find a difference between PTH and 
alendronate therapy [15]. A unique feature of the experi-
mental group is the cyclical 3-month PTH regimen al-
ternating with 3 months of alendronate. The comparison 
group was administered alendronate for at least 1 year. 
Cyclic PTH results in the early phase (bone formation) of 
PTH action [31] and thereby limits the bone remodeling 
phase. As the authors stated, the 3-month delay between 
PTH treatments may have been too short to observe an 
improvement in bone formation, given that bisphospho-
nates have an opposing effect on bone turnover compared 
to PTH. Additionally, the authors were only able to assess 
the efficacy of the first cycle of PTH followed by alendro-
nate and were unable to draw conclusions regarding sub-
sequent cycles. Studies of longer PTH cycles are needed to 
draw firm conclusions.
Comparative studies between PTH and bisphospho-
nates have found treatment with PTH to be superior in 
regards to bone formation and fusion [11-13] with the 
exception of one study which found no difference [15]. 
Animal studies have similarly concluded that PTH pro-
duces more mature bone formation and larger fusion 
masses [28]. However, maximum follow-up among these 
studies was 24 months [13,15] and long-term clinical data 
is unavailable. Insufficient long-term clinical outcome 
data prohibits making strong conclusions between fusion 
and outcomes in patients who received anti-resorptive 
or bone-producing medications. However, successful 
spinal fusion has been correlated with improved patient 
outcomes in long-term studies in patients who have not 
received these medications [32]. 
New data in fracture healing in rat models using anti-
sclerostin antibody has shown some promising results 
when used in conjunction with an osteoinductive agent 
such as bone morphogenetic protein-2 (BMP-2). In a 
rat fracture model, Tinsley et al. [27] showed that anti-
sclerostin antibody with BMP-2 had stronger biomechani-
cal properties than non-fractured femurs. Although this 
is study regarding fracture repair in an animal model, this 
agent has shown promise in bone healing, and may be on 
the horizon for use in spinal fusion alongside PTH and 
bisphosphonates for patients with osteoporosis undergo-
ing posterior spine fusion. 
The present study has several limitations. The analysis 
was limited by the integrity and sample sizes of the stud-
ies which were reviewed. Ideally, all studies included in 
this review would be limited to large-scale randomized 
controlled trials on humans, however this was not pos-
sible based on the available literature. As discussed ear-
lier, there is heterogeneity in treatment type, medication 
dosing, timing, and duration, as well as measurement of 
outcomes. Selection bias was also a concern in the retro-
spective studies included in this review. 
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Conclusions
Bisphosphonates have shown promise in both animal and 
human studies to be safe and effective in osteoporotic pa-
tients undergoing lumbar spinal fusion. Although the evi-
dence in the literature is heterogeneous, some conclusions 
regarding its efficacy may be drawn. PTH has also been 
shown to increase bone mass and rates of fusion com-
pared to controls. This data, however should be used cau-
tiously based on the nonuniformity and low sample sizes 
of the studies provided. Larger prospective randomized-
controlled trials are needed before firm conclusions can 
be made regarding changes in current clinical treatment 
strategies for this patient population. 
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